CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BioInfra Life Science Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BioInfra Life Science Inc
7F
SGI Building, 49, Daehak-ro, Jongno-gu
Phone: +82 23221687p:+82 23221687 SEOUL, 08513  South Korea Ticker: 266470266470

Business Summary
BioInfra Life Science Inc is a Korea-based company mainly engaged in the research and development and manufacture of protein chip contents. The Company provides diagnostic testing services and research services. The Company provides services such as multi-biomarker blood tests, diagnosis kit development, biomarker discovery, and peptide chip development.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023Yes----

General Information
Number of Employees: 15 (As of 12/31/2023)
Outstanding Shares: 20,106,847 (As of 11/6/2024)
Shareholders: 1,755
Stock Exchange: KON
Fax Number: +82 264991941


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024